MT-45*

MT-45 (IC-6) is an opioid analgesic drug invented in the 1970s by Dainippon Pharmaceutical Co. It is chemically a 1-substituted-4-(1,2-diphenylethyl)piperazine derivative, which is structurally unrelated to most other opioid drugs. Racemic MT-45 has around 80% the potency of morphine, with almost all opioid activity residing in the (S) enantiomer (the opposite stereochemistry from the related drug lefetamine). It has been used as a lead compound from which a large family of potent opioid drugs have been developed, including full agonists, partial agonists, and antagonists at the three main opioid receptor subtypes.

Recreational use of MT-45 has been associated with hearing loss and unconsciousness. MT-45 became a class A drug in the UK on 11 March 2015. MT-45 is banned in the Czech Republic. The Canadian Controlled Drugs and Substances Act was amended in 2016 to include the substance as a Schedule I substance. Possession without legal authority can result in maximum 7 years imprisonment. Further, Health Canada amended the Food and Drug Regulations in May, 2016 to classify MT-45 as a restricted drug. Only those with a law enforcement agency, person with an exemption permit or institutions with Minister's authorization may possess the drug in Canada.

Whole Blood
Post Mortem Blood
Urine
Oral Fluid
Hair
Meconium
Vitreous Humor
Tissue

Cross Reactivity

Analyte Compound
Cross Reactivity %
CR%
MT-45
LOD: 5 ng/mL
MT-45 100
3-hydroxy MT-45
139.3

All data in the above table refers to our whole blood matrix.

Microplate Readers Available

Product ds2 7

DS2

  • Fully automated compact reader
  • Processes 100 samples per run
  • Ideal for routine drug detection


Product elx800 cutout tox logo

ELx800

  • Semi-automated robust microplate reader
  • Reads 96 wells in 30 seconds
  • Ideal for routine drug detection

UK: +44 (0)28 9442 2413
USA: +1 304 728 2890